The abortion ban and mifepristone’s threatening rise


  • Mirha Ali Department of Medicine, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan
  • Jenelle Alvares Department of Medicine, Dow University of Health Sciences, Karachi, Sindh, Pakistan
  • Ayesha Muhammad Department of Programs and Research, SHINE Humanity, Karachi, Sindh, Pakistan



Post-abortion care, Health care, Mifepristone


The recent imposition and overrule of the Roe V. Wade abortion law by the US government has created havoc in the state, predicting an alarming rise in mifepristone’s self-usage. This abortion pill is a safer alternative than other methods of abortion which can lead to a rise in its overseas mailing. The potential threat of abuse and unsupervised ingestion of this abortion pill can cause detrimental complications, the emergency treatment of which has been stopped by health care providers. Additionally, the controversial debate on the overlap of post-abortion health care and legal investigations has generated fear among women to receive post-abortion care (PAC), if there is any complication, due to the fright of being prosecuted. This portrays a future threat of an increase in maternal mortality. Although, mifepristone’s use in other diseases is beneficial, instead of banning it, the main focus should be on providing safe post-abortion emergency care if needed.


Metrics Loading ...


Abortion procedures-medication-Better Health Channel. Available at: Accessed on 18 July 2022

Moseson H, Jayaweera R, Egwuatu I, Grosso B, Kristianingrum IA, Nmezi S et al. Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls. Lancet Glob Heal. 2022;10(1):e105-13.

Løkeland M, Iversen OE, Engeland A, Økland I, Bjørge L. Medical abortion with mifepristone and home administration of misoprostol up to 63 days’ gestation. Acta Obstet Gynecol Scand. 2014;93(7):647-53.

DeHart RM, Morehead MS. Mifepristone. Ann Pharmacother. 2001;35(6):707-19.

RU-486, drug, Britannica. Available at: Accessed on 18 July 2022.

Medication Abortion Now Accounts for More Than Half of All US Abortions, Guttmacher Institute. Available at: 2022/02/medication-abortion-now-accounts-more-half-all-us-abortions. Accessed on 19 July 2022.

Hemmerling A, Siedentopf F, Kentenich H. Emotional impact and acceptability of medical abortion with mifepristone: A German experience. J Psychosomatic Obstetr Gynecol. 2005;26:1:23-31.

Oakley RH, Cidlowski JA. The Biology of the Glucocorticoid Receptor: New Signaling Mechanisms in Health and Disease. J Allergy Clin Immunol. 2013;132(5):1033.

Mifepristone (Korlym): First FDA-Approved Medication for the Treatment of Cushing’s Syndrome-CSRF- Cushing’s Support and Research Foundation. Available at: Accessed on 22 July 2022.

Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29(8):1538-45.

Mifepristone-Corcept Therapeutics-AdisInsight. Available at: 800001657. Accessed on 20 July 2022.

Su YT, Chen JS, Tsai YR, Lan KC, Wu CC, Huang FJ. Mifepristone Directly Disrupts Mouse Embryonic Development in Terms of Cellular Proliferation and Maturation In Vitro. Toxics. 2021;9(11).

Creinin MD, Hou MY, Dalton L, Steward R, Chen MJ. Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2020;135(1):158-65.

Marmion PJ, Skop I. Induced Abortion and the Increased Risk of Maternal Mortality. Linacre Q. 2020;87(3):302-10.

Roe V. Wade: Women in states with bans can get pills from overseas. Available at: https://www.cnbc. com/2022/06/27/women-in-states-that-ban-abortion-will-still-be-able-to-get-abortion-pills-online-from-overseas.html. Accessed on 16 July 2022.






Review Articles